低β频段抑制作为DBS接触选择的工具,用于帕金森病中类似性-刚性症状的DBS接触选择

Joshua N Strelow1, Till A Dembek2, Juan C Baldermann3

  • 1University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Stereotactic and Functional Neurosurgery, Cologne, Germany.

概括

贝塔带抑制有效地预测了帕金森病 (PD) 患者的临床结果,这些患者接受了下丘脑深度大脑刺激 (STN-DBS). 低β频段抑制是选择最佳刺激接触的可靠生物标志物,提高治疗疗效.